9 results on '"Li, Yazhou"'
Search Results
2. Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders
- Author
-
Li, Yazhou, Vaughan, Kelli L., Wang, Yun, Yu, Seong-Jin, Bae, Eun-Kyung, Tamargo, Ian A., Kopp, Katherine O., Tweedie, David, Chiang, Cheng-Chuan, Schmidt, Keith T., Lahiri, Debomoy K., Tones, Michael A., Zaleska, Margaret M., Hoffer, Barry J., Mattison, Julie A., and Greig, Nigel H.
- Published
- 2024
- Full Text
- View/download PDF
3. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.
- Author
-
Bader, Miaad, Li, Yazhou, Lecca, Daniela, Rubovitch, Vardit, Tweedie, David, Glotfelty, Elliot, Rachmany, Lital, Kim, Hee Kyung, Choi, Ho-Il, Hoffer, Barry J., Pick, Chaim G., Greig, Nigel H., and Kim, Dong Seok
- Subjects
- *
MULTIPLE system atrophy , *BRAIN injuries , *CELL death , *GLUCAGON-like peptide 1 , *PARKINSON'S disease - Abstract
Abstract Traumatic brain injury (TBI) is a neurodegenerative disorder for which no effective pharmacological treatment is available. Glucagon-like peptide 1 (GLP-1) analogues such as Exenatide have previously demonstrated neurotrophic and neuroprotective effects in cellular and animal models of TBI. However, chronic or repeated administration was needed for efficacy. In this study, the pharmacokinetics and efficacy of PT302, a clinically available sustained-release Exenatide formulation (SR-Exenatide) were evaluated in a concussive mild (m)TBI mouse model. A single subcutaneous (s.c.) injection of PT302 (0.6, 0.12, and 0.024 mg/kg) was administered and plasma Exenatide concentrations were time-dependently measured over 3 weeks. An initial rapid regulated release of Exenatide in plasma was followed by a secondary phase of sustained-release in a dose-dependent manner. Short- and longer-term (7 and 30 day) cognitive impairments (visual and spatial deficits) induced by weight drop mTBI were mitigated by a single post-injury treatment with Exenatide delivered by s.c. injection of PT302 in clinically translatable doses. Immunohistochemical evaluation of neuronal cell death and inflammatory markers, likewise, cross-validated the neurotrophic and neuroprotective effects of SR-Exenatide in this mouse mTBI model. Exenatide central nervous system concentrations were 1.5% to 2.0% of concomitant plasma levels under steady-state conditions. These data demonstrate a positive beneficial action of PT302 in mTBI. This convenient single, sustained-release dosing regimen also has application for other neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple system atrophy and multiple sclerosis where prior preclinical studies, likewise, have demonstrated positive Exenatide actions. Highlights • PT302 is a sustained-release formulation of Exenatide that generates steady-state plasma levels. • PT302 post-treatment mitigates neuronal loss induced by mild TBI in mice. • PT302 post-treatment mitigates neuroinflammation induced by mild TBI in mice. • PT302 post-treatment mitigates behavioral impairments induced by mild TBI in mice. • All the above was achieved at clinically translatable doses of PT302. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Blast traumatic brain injury–induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.
- Author
-
Tweedie, David, Rachmany, Lital, Rubovitch, Vardit, Li, Yazhou, Holloway, Harold W., Lehrmann, Elin, Zhang, Yongqing, Becker, Kevin G., Perez, Evelyn, Hoffer, Barry J., Pick, Chaim G., and Greig, Nigel H.
- Abstract
Introduction Blast traumatic brain injury (B-TBI) affects military and civilian personnel. Presently, there are no approved drugs for blast brain injury. Methods Exendin-4 (Ex-4), administered subcutaneously, was evaluated as a pretreatment (48 hours) and postinjury treatment (2 hours) on neurodegeneration, behaviors, and gene expressions in a murine open field model of blast injury. Results B-TBI induced neurodegeneration, changes in cognition, and genes expressions linked to dementia disorders. Ex-4, administered preinjury or postinjury, ameliorated B-TBI–induced neurodegeneration at 72 hours, memory deficits from days 7–14, and attenuated genes regulated by blast at day 14 postinjury. Discussion The present data suggest shared pathologic processes between concussive and B-TBI, with end points amenable to beneficial therapeutic manipulation by Ex-4. B-TBI–induced dementia-related gene pathways and cognitive deficits in mice somewhat parallel epidemiologic studies of Barnes et al. who identified a greater risk in US military veterans who experienced diverse TBIs, for dementia in later life. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.
- Author
-
Salcedo, Isidro, Tweedie, David, Li, Yazhou, and Greig, Nigel H
- Subjects
TREATMENT of neurodegeneration ,BRAIN disease treatment ,CEREBROVASCULAR disease ,TYPE 2 diabetes ,GLUCAGON-like peptide 1 ,OXIDATIVE stress ,CELLULAR signal transduction ,ALZHEIMER'S disease ,NEUROPLASTICITY - Abstract
Like type-2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are an ever increasing, health, social and economic burden for developed Westernized countries. Age is an important risk factor in all of these; due to the rapidly increasing rise in the elderly population T2DM and neurodegenerative disorders, both represent a looming threat to healthcare systems. Whereas several efficacious drugs are currently available to ameliorate T2DM, effective treatments to counteract pathogenic processes of neurodegenerative disorders are lacking and represent a major scientific and pharmaceutical challenge. Epidemiological data indicate an association between T2DM and most major neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Likewise, there is an association between T2DM and stroke incidence. Studies have revealed that common pathophysiological features, including oxidative stress, insulin resistance, abnormal protein processing and cognitive decline, occur across these. Based on the presence of shared mechanisms and signalling pathways in these seemingly distinct diseases, one could hypothesize that an effective treatment for one disorder could prove beneficial in the others. Glucagon-like peptide-1 (GLP-1)-based anti-diabetic drugs have drawn particular attention as an effective new strategy to not only regulate blood glucose but also to reduce apoptotic cell death of pancreatic beta cells in T2DM. Evidence supports a neurotrophic and neuroprotective role of GLP-1 receptor (R) stimulation in an increasing array of cellular and animal neurodegeneration models as well as in neurogenesis. Herein, we review the physiological role of GLP-1 in the nervous system, focused towards the potential benefit of GLP-1R stimulation as an immediately translatable treatment strategy for acute and chronic neurological disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
- Author
-
Li, Yazhou, Tweedie, David, Mattson, Mark P., Holloway, Harold W., and Greig, Nigel H.
- Subjects
- *
GLUCAGON-like peptide 1 , *CELL proliferation , *NEUROBLASTOMA , *PROTEIN kinases , *NEURODEGENERATION - Abstract
J. Neurochem. (2010) 113, 1621–1631. Increasing evidence suggests that glucagon-like peptide-1 (GLP-1), an incretin hormone of current interest in type 2 diabetes, is neuroprotective in both cell culture and animal models. To characterize the neuroprotective properties of GLP-1 and associated underlying mechanisms, we over-expressed the GLP-1 receptor (GLP-1R) on human neuroblastoma SH-SY5Y cells to generate a neuronal culture system featuring enhanced GLP-1R signaling. In GLP-1R over-expressing SH-SY5Y (SH-hGLP-1R#9) cells, GLP-1 and the long-acting agonist exendin-4 stimulated cell proliferation and increased cell viability by 2-fold at 24 h at physiologically relevant concentrations. This GLP-1R-dependent action was mediated via the protein kinase A and phosphoinositide 3-kinase signaling pathways, with the MAPK pathway playing a minor role. GLP-1 and exendin-4 pretreatment dose-dependently protected SH-hGLP-1R#9 cells from hydrogen peroxide (H2O2)- and 6-hydroxydopamine-induced cell death. This involved amelioration of elevated caspase 3 activity, down-regulation of pro-apoptotic Bax and up-regulation of anti-apoptotic Bcl-2 protein. In the presence of 6-hydroxydopamine, GLP-1’s ability to lower caspse-3 activity was abolished with the phosphoinositide 3-kinase inhibitor, LY2940002, and partly reduced with the protein kinase A inhibitor, H89. Hence, GLP-1R mediated neurotrophic and anti-apoptotic actions co-contribute to the neuroprotective property of GLP-1 in neuronal cell cultures, and reinforce the potential therapeutic value of GLP-1R agonists in neurodegenerative disorders involving oxidative stress. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
7. Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
- Author
-
Kopp, Katherine O., Glotfelty, Elliot J., Li, Yazhou, Lahiri, Debomoy K., and Greig, Nigel H.
- Subjects
- *
TYPE 2 diabetes , *NEURODEGENERATION , *ALZHEIMER'S disease , *MORBID obesity , *THERAPEUTICS , *EXENATIDE , *PARKINSON'S disease , *NEUROPROTECTIVE agents - Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonist-based drugs (incretin mimetics) have meaningfully impacted current treatment of type 2 diabetes mellitus (T2DM), and their actions on satiety and weight loss have led to their use as an obesity medication. With multiple pleotropic actions beyond their insulinotropic and weight loss ones, including anti-inflammatory and anti-insulin-resistant effects selectively mediated by their receptors present within numerous organs, this drug class offers potential efficacy for an increasing number of systemic and neurological disorders whose current treatment is inadequate. Among these are a host of neurodegenerative disorders that are prevalent in the elderly, such as Parkinson's and Alzheimer's disease, which have bucked previous therapeutic approaches. An increasing preclinical, clinical, and epidemiological literature suggests that select incretin mimetics may provide an effective treatment strategy, but 'which ones' for 'which disorders' and 'when' remain key open questions. • GLP-1 receptor agonists (RA) have become widely prescribed drugs (type 2 diabetes/weight loss). • GLP-1RA repurposing is being clinically evaluated in neurodegenerative disorders of the elderly. • Clinical trials of GLP-RAs are promising in Parkinson's disease – Alzheimer studies are ongoing. • GLP-1RAs with action on GIP and other receptors are available and may offer greater benefit. • Selection of the best GLP-1RAs, most likely patients to respond and best time to treat is critical. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
- Author
-
Kopp, Katherine O., Glotfelty, Elliot J., Li, Yazhou, and Greig, Nigel H.
- Subjects
- *
THERAPEUTICS , *NEURODEGENERATION , *TYPE 2 diabetes , *ALZHEIMER'S disease , *NEUROINFLAMMATION , *INSULIN receptors , *PITUITARY adenylate cyclase activating polypeptide , *DOPAMINE receptors - Abstract
Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory pathways have yet to be effectively targeted in clinical treatments for such diseases. Interestingly, increased inflammation and neurodegenerative disease risk have been associated with type 2 diabetes mellitus (T2DM) and insulin resistance (IR), suggesting that treatments that mitigate T2DM pathology may be successful in treating neuroinflammatory and neurodegenerative pathology as well. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that promotes healthy insulin signaling, regulates blood sugar levels, and suppresses appetite. Consequently, numerous GLP-1 receptor (GLP-1R) stimulating drugs have been developed and approved by the US Food and Drug Administration (FDA) and related global regulatory authorities for the treatment of T2DM. Furthermore, GLP-1R stimulating drugs have been associated with anti-inflammatory, neurotrophic, and neuroprotective properties in neurodegenerative disorder preclinical models, and hence hold promise for repurposing as a treatment for neurodegenerative diseases. In this review, we discuss incretin signaling, neuroinflammatory pathways, and the intersections between neuroinflammation, brain IR, and neurodegenerative diseases, with a focus on AD and PD. We additionally overview current FDA-approved incretin receptor stimulating drugs and agents in development, including unimolecular single, dual, and triple receptor agonists, and highlight those in clinical trials for neurodegenerative disease treatment. We propose that repurposing already-approved GLP-1R agonists for the treatment of neurodegenerative diseases may be a safe, efficacious, and cost-effective strategy for ameliorating AD and PD pathology by quelling neuroinflammation. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. An extended release GLP-1 analogue increases α-synuclein accumulation in a mouse model of prodromal Parkinson's disease.
- Author
-
Bergkvist, Liza, Johnson, Michaela E., Mercado, Gabriela, Steiner, Jennifer A., Meyerdirk, Lindsay, Schulz, Emily, Madaj, Zachary, Ma, Jiyan, Becker, Katelyn, Li, Yazhou, and Brundin, Patrik
- Subjects
- *
PARKINSON'S disease , *LABORATORY mice , *GLUCAGON-like peptide 1 , *ANIMAL disease models , *DOPAMINERGIC neurons , *TYPE 2 diabetes - Abstract
The repurposing of drugs developed to treat type 2 diabetes for the treatment of Parkinson's disease (PD) was encouraged by the beneficial effect exerted by the glucagon-like peptide 1 (GLP-1) analogue exenatide in a phase 2 clinical trial. The effects of GLP-1 analogues have been investigated extensively using rodent toxin models of PD. However, many of the toxin-based models used lack robust α-synuclein (α-syn) pathology, akin to the Lewy bodies and neurites seen in PD. One prior study has reported a protective effect of a GLP-1 analogue on midbrain dopamine neurons following injection of α-syn preformed fibrils (PFF) into the striatum. Here, we used olfactory bulb injections of PFF as a model of prodromal PD and monitored the effect of a long-acting GLP-1 analogue on the propagation of α-syn pathology in the olfactory system. Thirteen weeks after PFF injection, mice treated with long-acting the GLP-1 analogue had a significant increase in pathological α-syn in brain regions connected to the olfactory bulb, accompanied by signs of microglia activation. Our results suggest that the nature of the neuronal insult and intrinsic properties of the targeted neuronal population markedly influence the effect of GLP-1 analogues. • Increased α-synuclein pathology in GLP-1 analogue treated prodromal mouse model. • Accompanied by a change in microglial morphology indicating microglia activation. • No change in neuronal cell survival nor astrocyte activation is observed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.